Detection of miR-92a and miR-21 in stool samples as potential screening biomarkers for colorectal cancer and polyps

Objective The detection of molecular markers in stool samples is a potential strategy for colorectal cancer (CRC) screening. This study evaluated the feasibility of detecting miR-21 and miR-92a in stool samples of patients with CRC or polyps. Methods The reproducibility of detection and stability of stool-based microRNA were evaluated. Stool samples were collected from 88 patients with CRC, 57 patients with colorectal polyps and 101 healthy controls. MiRNA levels in CRC tissues and stool samples were detected by real-time quantitative reverse transcription PCR. Stool miR-21 and miR-92a levels were compared before and after the removal of tumour or advanced adenoma. Results The study demonstrated that stool-based miRNA were stable with highly reproducible detection. The expression of miR-21 and miR-92a was significantly higher in CRC tissues compared with their adjacent normal tissues (p<0.0001). Patients with CRC had a significantly higher stool miR-21 level (p<0.01) and miR-92a level (p<0.0001) compared with normal controls. Stool miR-92a, but not miR-21, was significantly higher in patients with polyps than in controls (p<0.0001). At a cut-off value of 435 copies/ng of stool RNA, miR-92a had a sensitivity of 71.6% and 56.1% for CRC and polyp, respectively, and a specificity of 73.3%. In addition, the stool miR-92a level demonstrated a higher sensitivity for distal CRC than proximal CRC (p<0.05), and a higher sensitivity for advanced adenoma than minor polyps (p<0.05). Removal of tumour resulted in reduced stool miR-21 and miR-92a levels (p<0.01), and the removal of advanced adenoma resulted in a reduction of the stool miR-92a level (p<0.05). Conclusion Stool miRNA are useful for screening CRC and polyps.

[1]  Zuoren Yu,et al.  The DNA/RNA-binding protein, translin, binds microRNA122a and increases its in vivo stability. , 2008, Journal of andrology.

[2]  W. Leung,et al.  Detection of Hypermethylated DNA or Cyclooxygenase-2 Messenger RNA in Fecal Samples of Patients With Colorectal Cancer or Polyps , 2007, The American Journal of Gastroenterology.

[3]  A. Jemal,et al.  Global Cancer Statistics , 2011 .

[4]  P. Hardt,et al.  Measurement of fecal pyruvate kinase type M2 (tumor M2-PK) concentrations in patients with gastric cancer, colorectal cancer, colorectal adenomas and controls. , 2003, Anticancer research.

[5]  F. Chan,et al.  Asia Pacific consensus recommendations for colorectal cancer screening , 2008, Gut.

[6]  C. Fraser,et al.  Effect of delay in sampling on haemoglobin determined by faecal immunochemical tests , 2008, Annals of clinical biochemistry.

[7]  D. Ransohoff,et al.  Fecal DNA versus fecal occult blood for colorectal-cancer screening in an average-risk population. , 2004, The New England journal of medicine.

[8]  Farid E Ahmed,et al.  Diagnostic microRNA markers for screening sporadic human colon cancer and active ulcerative colitis in stool and tissue. , 2009, Cancer genomics & proteomics.

[9]  S. Bingham,et al.  Analysis of minichromosome maintenance proteins as a novel method for detection of colorectal cancer in stool , 2002, The Lancet.

[10]  E. Ng,et al.  Differential expression of microRNAs in plasma of patients with colorectal cancer: a potential marker for colorectal cancer screening , 2009, Gut.

[11]  Loyal A Goff,et al.  Differential regulation of microRNA stability. , 2010, RNA.

[12]  C. Croce,et al.  A microRNA expression signature of human solid tumors defines cancer gene targets , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[13]  Francesco Rulli,et al.  Clusterin in Stool: A New Biomarker for Colon Cancer Screening? , 2009, The American Journal of Gastroenterology.

[14]  H. Sugimura,et al.  Fecal Cyclooxygenase 2 Plus Matrix Metalloproteinase 7 mRNA Assays as a Marker for Colorectal Cancer Screening , 2009, Cancer Epidemiology Biomarkers & Prevention.

[15]  T. Leung,et al.  Detection and characterization of placental microRNAs in maternal plasma. , 2008, Clinical chemistry.

[16]  A. Verbeek,et al.  False negative fecal occult blood tests due to delayed sample return in colorectal cancer screening , 2009, International journal of cancer.

[17]  J. Ferlay,et al.  Global Cancer Statistics, 2002 , 2005, CA: a cancer journal for clinicians.

[18]  Yonggoo Kim,et al.  Gastrointestinal tract cancer screening using fecal carcinoembryonic antigen. , 2003, Annals of clinical and laboratory science.

[19]  A. Jemal,et al.  Global cancer statistics , 2011, CA: a cancer journal for clinicians.

[20]  M. A. van de Wiel,et al.  MiR-17-92 cluster is associated with 13q gain and c-myc expression during colorectal adenoma to adenocarcinoma progression , 2009, British Journal of Cancer.

[21]  H. Horvitz,et al.  MicroRNA expression profiles classify human cancers , 2005, Nature.

[22]  D. Sargent,et al.  Stool DNA and Occult Blood Testing for Screen Detection of Colorectal Neoplasia , 2008, Annals of Internal Medicine.

[23]  Michael Z Michael,et al.  Reduced accumulation of specific microRNAs in colorectal neoplasia. , 2003, Molecular cancer research : MCR.

[24]  H. Baba,et al.  MicroRNA Expression Profiling of Exfoliated Colonocytes Isolated from Feces for Colorectal Cancer Screening , 2010, Cancer Prevention Research.

[25]  H. Sugimura,et al.  Potential usefulness of detecting cyclooxygenase 2 messenger RNA in feces for colorectal cancer screening. , 2004, Gastroenterology.

[26]  S. Kanaoka,et al.  Factors that contribute to faecal cyclooxygenase-2 mRNA expression in subjects with colorectal cancer , 2010, British Journal of Cancer.

[27]  J. Lupton,et al.  Quantification of human intestinal gene expression profiles using exfoliated colonocytes: a pilot study , 2003, Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals.

[28]  X. Agirre,et al.  Identification by Real-time PCR of 13 mature microRNAs differentially expressed in colorectal cancer and non-tumoral tissues , 2006, Molecular Cancer.

[29]  Brian S. Roberts,et al.  The colorectal microRNAome. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[30]  Daniel B. Martin,et al.  Circulating microRNAs as stable blood-based markers for cancer detection , 2008, Proceedings of the National Academy of Sciences.

[31]  C. Boland,et al.  Fecal MicroRNAs as Novel Biomarkers for Colon Cancer Screening , 2010, Cancer Epidemiology, Biomarkers & Prevention.

[32]  George A Calin,et al.  MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. , 2008, JAMA.